Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

Journal of Infectious Diseases

Volumn 185, Issue 5, 2002, Pages 599-607

  Benson, Constance A ^a   Deeks, Steven G ^b   Brun, Scott C ^d   Gulick, Roy M ^g   Eron, Joseph J ^h   Kessler, Harold A ^e   Murphy, Robert L ^f   Hicks, Charles ^h   King, Martin ^d   Wheeler, David ⁱ   Feinberg, Judith ^j   Stryker, Richard ^c   Sax, Paul E ^k   Riddler, Sharon ^l   Thompson, Melanie ^m   Real, Kathryn ^d   Hsu, Ann ^d   Kempf, Dale ^d   Japour, Anthony J ^d   Sun, Eugene ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Tower ID Medical Associates ^*  (United States)

^d Abbott Laboratories   (United States)

^e RUSH MEDICAL COLLEGE   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Infectious Disease Physicians   (United States)

^j UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^m AIDS Research Consortium of Atlanta   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; PROSPECTIVE STUDIES; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0036499067     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/339014     Document Type: Article

References (41)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
3. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-Week follow-up
4. Durable effect of Viracept (nelfinavir mesylate, NFV) in triple combination therapy
5. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
6. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure
7. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
8. Reduced antiviral drug susceptibility among patients with primary HIV infection
9. Can baseline genotype predict response to salvage therapy with nelfinavir?
10. Resistance mutations as predictor of response to salvage therapy
11. 60-Week virologic responses to a ritonavir/saquinavir containing regimen in patients who had previously failed nelfinavir
12. Randomized trial of abacavir (ABC) and nelfinavir (NFV) in combination with efavirenz (EFV) and adefovir dipivoxil (ADV) as salvage therapy in patients with virologic failure receiving indinavir (IDV)
13. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
14. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
15. Baseline resistance and virological response to mega-HAART salvage therapies
16. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359
17. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
18. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
19. + subjects
20. trough inhibitory quotient predicts virologic response to ABT-378/ritonavir (ABT-378/r) therapy in treatment-experienced patients
21. Response to ritonavir (RTV) intensification in indinaivr (IDV) recipients is highly correlated with virtual inhibitory quotient
22. Assessment of plasma protein binding of lopinavir (LPV) and ritonavir (RTV): In vitro and ex vivo data from HIV-infected patients and healthy volunteers
23. + patients: Follow-up beyond 2 years and viral load suppression below 3 copies/mL
24. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-Week results
25. A new ultrasensitive assay for quantitation of HIV-1 RNA in plasma
26. Comparative performance of three viral load assays on human immunodeficiency virus type 1 (HIV-1) isolates representing group M (subtypes A to G) and group O: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR version 1.5, and Quantiplex HIV-1 RNA version 3.0
27. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS Clinical Trial Group Protocol 333
28. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
29. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens
30. Combined nelfinavir/saquinavir protease inhibitor treatment in a BID regimen as salvage therapy in advanced HIV disease
31. Long term viral suppression using quadruple drug combination therapy in treatment-experienced HIV/ADS patients, following initial protease failure
32. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
33. Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors
34. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: Results from a community-based study
35. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
36. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
37. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy failed
38. Assessment of pharmacokinetic interactions between Kaletra (lopinavir/ritonavir or ABT-378/r) and nevirapine in pediatric subjects
39. HIV protease inhibitors: Immunological insights